URGN
UroGen Pharma Ltd
41.40$
+2.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | 0.2% | 7.4% | 159.8% | 266.7% | 8.6% | 10.7% | 11.9% | 11.3% | 9.8% | 11.3% | |
| – | – | – | 99.8% | 92.6% | -59.8% | 100.0% | 91.4% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% | |
| – | – | – | 58.7% | 229.2% | 3,274.3% | 273,872.2% | 401.0% | 99.2% | 82.2% | 55.1% | 63.2% | 61.1% | |
| – | – | – | 36.6% | 108.0% | 3,508.1% | 334,438.9% | 764.6% | 83.1% | 128.7% | 109.2% | 134.0% | 141.3% | |
| – | – | – | 95.3% | 337.2% | 6,782.4% | 608,311.1% | 1,165.6% | 281.4% | 210.9% | 167.9% | 197.2% | 202.4% | |
| – | – | – | 4.6% | -244.5% | -6,842.2% | -608,211.1% | -1,074.2% | -192.1% | -122.8% | -79.2% | -107.1% | -113.7% | |
| – | – | – | 0.0% | 0.0% | 0.0% | 1,577.8% | 31.1% | 36.3% | 13.1% | 17.8% | 13.9% | 30.8% | |
| – | – | – | -11.1% | -244.9% | -6,696.1% | -584,144.4% | -1,060.3% | -227.7% | -167.9% | -118.9% | -137.2% | -139.7% | |
| – | – | – | 0.0% | 0.2% | 11.1% | -25,644.4% | 28.6% | 3.0% | 2.7% | 4.7% | 3.1% | 0.1% | |
| – | – | – | -11.1% | -245.2% | -6,707.2% | -584,144.4% | -1,088.9% | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% | |
| – | – | – | 5.8% | -242.0% | -6,805.2% | -600,855.6% | -1,056.8% | -225.9% | -118.4% | -73.0% | -105.5% | -123.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.